Industry / Spain
Biotech Breakthrough Gets EU Approval
October 2007 | Industry NewsPharmamar, a subsidiary of Spanish drugmaker Zeltia , has announced that its cancer drug Yondelis (trabectedin) has gained European Union (EU) approval.
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Western Europe Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Western Europe Pharma & Healthcare Insight please click on the trial link below.
